Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19334597 | 0.98 | PLA2G4A (0.36) | PLA2G4AL3MBTL1HSPA5CTSKNR1I2 | |
| SCHEMBL18948435 | 0.98 | PLA2G4A (0.36) | PLA2G4AL3MBTL1HSPA5CTSKNR1I2 | |
| SCHEMBL18430567 | 0.98 | PLA2G4A (0.36) | PLA2G4AL3MBTL1HSPA5CTSKNR1I2 | |
| SCHEMBL29325457 | 0.98 | PLA2G4A (0.36) | PLA2G4AL3MBTL1HSPA5CTSKNR1I2 | |
| SCHEMBL21217035 | 0.98 | PLA2G4A (0.36) | PLA2G4AL3MBTL1HSPA5CTSKNR1I2 | |
| SCHEMBL28578071 | 0.93 | L3MBTL1 (0.34) | PLA2G4AL3MBTL1HSPA5CTSKFBP1 | |
| SCHEMBL29865290 | 0.92 | NR1I2 (0.38) | PLA2G4AL3MBTL1NR1I2FBP1 | |
| SCHEMBL12193817 | 0.83 | FBP1 (0.37) | HSPA5FBP1 | |
| SCHEMBL1670553 | 0.83 | CA2 (0.39) | PLA2G4AL3MBTL1 | |
| SCHEMBL7763980 | 0.81 | PLA2G4A (0.34) | PLA2G4AL3MBTL1HSPA5CTSKFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696713-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190194245-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2019-06-27 | — | — | US | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696713-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | PLA2G4A 996/4885L3MBTL1 4658/4885HSPA5 387/4885 |
| US-20190194245-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | PLA2G4A 996/4885L3MBTL1 4658/4885HSPA5 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.